50 results on '"Bláha V"'
Search Results
2. Changes of the complement system and rheological indicators after therapy with rheohemapheresis
3. Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration
4. The decrease of mean platelet volume after extracorporeal LDL-cholesterol elimination
5. Extracorporeal LDL cholesterol elimination (25 years of experience in CZ)
6. Changes of serum fetuin-a in aged patients who undergone transcatheter aortic valve implantation or balloon angioplasty for the treatment of aortic stenosis
7. Effects of body weight reduction on plasma fibroblast growth factor 21 in obese patients with type 1 diabetes mellitus
8. LDL-apheresis in Czech Republic
9. Comparison of effects of diabetic enteral nutrition and standard enteral nutrition on postprandial level of free fatty acids – A pilot study
10. Lipoprotein associated phospholipase A2 mass level is elevated after transcatheter aortic valve implantation or ballon angioplasty in elderly patients
11. The role of VEGF in the elderly diabetic patients undergoing endovascular therapy of advanced atherosclerotic aortic valve stenosis
12. Dynamics of selected thrombocyte and coagulation cascade parameters after the ldl-cholesterol elimination therapy in familial hypercholesterolemia
13. 526 INCREASED PREGNANCY ASSOCIATED PROTEIN A (PAPP-A) PREDICTED EARLY SURVIVAL IN CHRONIC HEMODIALYSIS (HD) PATIENTS
14. 468 THE DECREASE OF MEAN PLATELET VOLUME AFTER EXTRACORPOREAL LDL-CHOLESTEROL ELIMINATION IN PATIENTS WITH SEVERE FAMILIAL HYPERCHOLESTEROLEMIA
15. 84 CHOLESTEROL METABOLISM IN PATIENTS WITH DIABETES MELLITUS TYPE 1 AND IMPACT OF WEIGHT REDUCTION
16. P165 ASYMMETRIC DIMETHYLARGININE (ADMA) PREDICTS SKIN BLOOD FLOW DURING HEMODIALYSIS (HD)
17. Abstract: P1227 INTERVENTION IMPROVES LEVELS OF HDL FOLLOWED BY DECREASE IN MCP-1 AND INCREASED TWO-YEAR SURVIVAL OF HEMODIALYZED (HD) PATIENTS
18. Abstract: P1226 MALNUTRITION, INFLAMMATION AND ATHEROSCLEROSIS INCREASE MORTALITY OF HEMODIALYSED (HD) PATIENTS
19. Abstract: P951 THE IMPACT OF HEMODIALYSIS UPON ATORVASTATIN LEVELS IN PATIENTS WITH END STAGE RENAL DISEASE
20. Abstract: P849 HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CZ (A 15YEAR EXPERIENCE WITH EXTRACORPOREAL LDL-ELIMINATION)
21. Abstract: 1096 ATHEROSCLEROSIS AND INFLAMMATION IN HEMODIALYSIS (HD) PATIENTS: THE IMPACT OF INTERVENTION
22. CONCOMITANT ADMINISTRATION OF STATIN AND FENOFIBRATE IN PATIENTS WITH MIXED DYSLIPIDEMIA
23. CHANGES OF LABORATORY PARAMETERS DURING LONG-TERM EXTRACORPOREAL LDL-CHOLESTEROL ELIMINATION
24. DETERMINATION OF STATINS IN BIOLOGICAL MATERIALS
25. OUTCOME COMPARISON TO TAKE ADVANTAGE OF MODIFIED PLATELETS AGGREGATION AND PFA-100 ANALYSIS TO RATIONALIZE THERAPEUTIC LDL-APHERESIS PROCEDURE
26. INTERVENTION IMPROVES ATHEROGENIC LOW-GRADE INFLAMMATION MARKED BY MACROPHAGE CHEMOATTRACTANT PROTEIN-1 (MCP-1) IN END STAGE RENAL DISEASE (ESRD) PATIENTS
27. MALNUTRITION, INFLAMMATION, ATHEROSCLEROSIS AND CALCIFICATION (MIAC SYNDROME) NEGATIVELY INFLUENCE PERIPHERAL BLOOD FLOW DURING HEMODIALYSIS (HD)
28. PO23-766 EZETIMIBE, STATIN AND LDL-APHERESIS IN COMBINED TREATMENT OF SEVERE HYPERCHOLESTEROLEMIA
29. PO22-720 THERAPEUTICAL INTERVENTION IMPROVING THE COURSE OF ATHEROSCLEROSIS MARKED BY LIPOPOLYSACHARIDE BINDING PROTEIN (LBP) IN END STAGE RENAL DISEASE PATIENTS
30. PO22-721 A PROSPECTIVE TRIAL TO TAKE ADVANTAGE OF PFA-100 ANALYSIS TO RATIONALIZE THERAPEUTIC LDL-APHERESIS PROCEDURE
31. PO13-354 HEMORHEOTHERAPY IN ATHEROSCLEROSIS – OUR MODIFICATION OF THERAPEUTIC PROCEDURE
32. PO13-352 VERIFICATION OF A COMPUTER CONTROLLED MODEL FOR LDL-APHERESIS OPTIMIZATION IN CLINICAL PRACTICE
33. PO3-65 DECREASED ATHEROGENIC LIPOPROTEINS LINKED TO AGE RELATED MACULAR DEGENERATION (ARD): IMPACT OF HAEMORHEOPHERESIS
34. Th-P16:317 Performance of LDL-apheresis and its relation to haemostasis
35. Th-P16:316 Long lasting LDL-apheresis in familial hyperlipoproteinaemia (ten years experience)
36. Th-P16:314 Endothelial dysfunction, inflammation and macrophage activation: The impact of LDL-apheresis on atherogenesis
37. Th-P16:315 Endoglin — Its significance during LDL-cholesterol elimination therapy
38. We-P11:60 The impact of atorvastatin on endothelial dysfunction and cholesterol turnover in patients with type 2 diabetes mellitus and cardiovascular disease
39. T07-P-001 Haemostasis and LDL-apheresis in familial hypercholesterolaemia
40. T07-P-002 LDL-lowering immunoapheresis is well tolerated and safe procedure in familial hyperlipoproteinaemia
41. T03-P-019 Changes of cholesterol metabolism in nonagenarians
42. W16-P-089 Extracorporal plasmapheresis in the treatment of severe hyperlipidaemia in patient with polymyositis
43. W16-P-053 Computer aided optimization and standardization of the procedures in lipid lowering immunotherapy
44. W16-P-008 Assessment of absorber efficacy during LDL-apheresis
45. W16-P-009 Relation of carotid intima-media thickness and lipoperoxidation during long-term aggressive lipid lowering with LDL apheresis
46. W12-P-006 The impact of abnormalities of fatty acid metabolism in nonagenarians with coronary artery disease
47. W01.132 Relation of carotid intima-media thickness and endothelial dysfunction during long-term aggressive lipid lowering with LDL apheresis
48. Lipids as risk factors of CVD development
49. The rebound of VLDL-, IDL-, LDL- and HDL-fatty acids versus lipid peroxidation post LDL-apheresis
50. Fatty acids content of cell membranes and plasma lipoproteins during LDL-apheresis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.